[Show abstract][Hide abstract] ABSTRACT: Visfatin with the official gene name pre-B cell colony-enhancing factor 1 (PBEF) and the protein name nicotinamide phosphoribosyltransferase (NAMPT) is a recently discovered adipocyte-secreted protein that was shown by some to be associated with visceral fat and insulin resistance. To explore the link between PBEF/NAMPT/visfatin and lipid metabolism, we analyzed the relation of its plasma level with several parameters of adiposity, insulin resistance and the circulating blood lipid profile in a group of general population (n = 40) and a group of subjects who are genetically predisposed to insulin resistance and hyperlipidemia (n = 35). In both groups and pooled cohort, PBEF/NAMPT/visfatin lacked association with whole body adiposity, but correlated positively with HDL-cholesterol and negatively with triglycerides. The data suggested a negative correlation of the PBEF level with visceral fat and insulin resistance. But this negative correlation completely disappeared after adjustment for lipid profile. We concluded that circulating PBEF/NAMPT/visfatin level is an indicator of beneficial lipid profile in non-diabetic Caucasian subjects. The relation to lipid metabolism does not depend on visceral obesity and insulin resistance, but may be linked to its enzymatic function in NAD metabolism.
Pflügers Archiv - European Journal of Physiology 10/2007; 454(6):971-6. DOI:10.1007/s00424-007-0262-y · 4.10 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Adipose tissue has recently been identified as an endocrine organ. Visfatin is a novel adipocytokine predominantly secreted from visceral adipocytes. Visceral obesity is an important component of metabolic syndrome; however, the relationship between visfatin levels and metabolic syndrome is not clear. The purpose of this study was to explore the association between visfatin levels and anthropometry and parameters of metabolic syndrome. Anthropometric measurements included height, weight, body mass index, waist and hip circumferences, waist-to-hip ratio, and blood pressure. Metabolic parameters including fasting serum visfatin, fasting serum insulin and fasting plasma glucose, lipid profiles, and uric acid levels were measured. Data of 500 subjects (244 men and 256 women) were used for the analysis. There was no significant difference in serum visfatin levels between male and female subjects. Visfatin correlated negatively with body mass index (beta = -.011, P = .025) in male subjects; however, visfatin did not correlate with any other anthropometric or any metabolic parameters in male subjects. There was no correlation between visfatin levels and any anthropometric parameters in female subjects; however, it did correlate positively with high-density lipoprotein cholesterol levels (beta = .126, P = .006) and correlate negatively with low-density lipoprotein cholesterol levels (beta = -.039, P = .010) in female subjects. In conclusion, visfatin is not related to most anthropometric parameters and most parameters of metabolic syndrome. It may play a role in cholesterol homeostasis in women.
[Show abstract][Hide abstract] ABSTRACT: Visfatin (also known as pre-B cell colony-enhancing factor or PBEF) is a cytokine that is highly expressed in visceral fat and whose blood levels correlate with obesity. Originally isolated as a secreted factor that promotes the growth of B cell precursors and recently found to act as an insulin analog on the insulin receptor, its pathophysiological role in humans remains largely unknown.
In this study we investigated whether plasma visfatin level is altered in patients with type 2 diabetes mellitus (T2DM).
Plasma visfatin as well as adiponectin and resistin concentrations were measured through ELISA in type 2 diabetic and nondiabetic subjects.
A total of 61 patients with T2DM and 59 sex- and age-matched nondiabetic subjects were studied. Plasma visfatin was found to be elevated in patients with T2DM (31.9 +/- 31.7 vs. 15.8 +/- 16.7 ng/ml, P = 0.002). In contrast, adiponectin was decreased (4.3 +/- 2.5 vs. 30.8 +/- 10.3 microg/ml, P < 0.001), whereas plasma resistin level did not differ between the groups. Increasing concentrations of visfatin were independently and significantly associated with T2DM. Multiple logistic regression analysis revealed visfatin as an independent association factor for T2DM, even after full adjustment of known biomarkers. The association between adiponectin and T2DM was no longer significant after adjustments for body mass index or waist to hip ratio. In a multiple linear regression analysis, only waist to hip ratio was independently associated with plasma visfatin level.
Our results indicate that visfatin may play a role in the pathogenesis of T2DM.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.